Injection of Tenoxicam Versus Arthrocentesis Alone in the Treatment of Temporomandibular Joint Osteoarthritis

• Status: Completed
• Trial end date: 2022-04-21
• Target enrollment: 0
• Participant gender: All

Summary

The aim of the study is to examine the effectiveness of arthrocentesis plus tenoxicam injection and to compare it with arthrocentesis alone in patients with TMJ-OA.

Thirty patients with TMJ-OA who were treated randomly with either arthrocentesis plus tenoxicam injection (TX group) or arthrocentesis alone (control group) were examined. Maximum mouth opening (MMO), visual analog scale (VAS) pain values, and joint sounds were the outcome variables, which were evaluated at pre-treatment and at 1, 4, 12, and 24 weeks after treatment.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Ataturk University
• Treatments: Tenoxicam

Criteria

Inclusion Criteria:

• Clinical and radiological diagnosis of TMJ-OA

• 18 years of age and older

• Sufficient clinical data at baseline and follow-up.

Exclusion Criteria:

• Uncontrolled systemic disease

• Neurological disease

• Previous TMJ surgery

• Malignant disease in the head and neck region